Nasopharyngeal cancer therapeutic pipeline analysis is likely to grow mainly due to the rising prevalence of nasopharyngeal cancer, globally. Some of the main factors driving the pipeline analysis for nasopharyngeal cancer includes increasing geriatric population, rising tobacco and alcohol consumption and increasing prevalence of nasopharyngeal cancer, untapped market as being a rare form of head and neck cancer and increasing health awareness. According to American Cancer Society, the nasopharyngeal cancer is more common in some parts of North Africa and Asia, particularly in Southern China. It is also more common in countries such as Canada and Alaska and among some immigrant groups in the U.S., such as recent Chinese immigrants. Nasopharyngeal cancer is found to be more prevalent in males as compared to females.
Nasopharyngeal cancer is the rarest form of head and neck cancer. Nasopharyngeal cancer is the tumor that occurs in nasopharynx which is the upper part of the throat behind the nose and near the base of skull. Two different types of tumors that can develop in nasopharynx include benign tumors and malignant tumors. Some of the risks factors for nasopharyngeal cancer include salt-cured fish and meat rich diet, epstein-barr viral infection and increasing tobacco and alcohol consumption. The disease occurs usually more in people who are under 55years of age and have a family history of nasopharyngeal cancer or have the chances to develop Epstein-barr viral infection. The symptoms of nasopharyngeal cancer include blurred vision, ear infection, headache, nose bleeding, lump in neck and numbness. Nasopharyngeal cancer is diagnosed by consulting an otolaryngologist for the physical examination. Further, chest X-ray, CT scan, MRI, ultrasound, blood tests, Epstein-barr viral infection testing and biopsy are done for the confirmation of the disease. The treatment for nasopharyngeal cancer includes, chemotherapy, radiation therapy, surgery and biological drug treatment.
Tessa Therapeutics Pte Ltd. is developing a drug by the name TT10 for the improvement of nasopharyngeal cancer. TT10 is being developed using Virus-Specific T Cell (VST) technology platform, which increases its target specificity, high tumor penetrance, lower chance of tumor escape and strong persistence. It has also received orphan drug designation for head and neck cancer by the U.S. Food and Drug Administration. Novartis AG is currently developing PDR001, which is in Phase II stage of clinical trial. PDR001 is a monoclonal antibody which effectively inhibits programmed cell death protein 1 (PDCD 1). Celgene Corp. is in the process of developing CC-486 for the treatment of nasopharyngeal cancer. It is currently in Phase II stage of development and acts as a small molecule that inhibits DNA methylation. arGEN-X BVBA is developing ARGX-110, which is in Phase IIclinical trial, and is a CD70 antigen inhibitor.
Some of the companies having a pipeline of nasopharyngeal cancer therapeutics include Atara Biotherapeutics, Inc., AVEO Pharmaceuticals, Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, arGEN-X BVBA, Merck & Co., Inc., Tessa Therapeutics Pte Ltd.